GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Price-to-Tangible-Book

HLVX (HilleVax) Price-to-Tangible-Book : 0.61 (As of May. 10, 2025)


View and export this data going back to 2022. Start your Free Trial

What is HilleVax Price-to-Tangible-Book?

As of today (2025-05-10), HilleVax's share price is $1.90. HilleVax's Tangible Book per Share of Dec. 2024 for the quarter that ended in Dec. 2024 was $3.11. Hence, HilleVax's Price to Tangible Book Ratio of today is 0.61.

The historical rank and industry rank for HilleVax's Price-to-Tangible-Book or its related term are showing as below:

HLVX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.47   Med: 2.25   Max: 3.48
Current: 0.63

During the past 5 years, HilleVax's highest Price to Tangible Book Ratio was 3.48. The lowest was 0.47. And the median was 2.25.

HLVX's Price-to-Tangible-Book is ranked better than
89.26% of 1201 companies
in the Biotechnology industry
Industry Median: 2.58 vs HLVX: 0.63

A closely related ratio is called PB Ratio. As of today, HilleVax's share price is $1.90. HilleVax's Book Value per Sharefor the quarter that ended in Dec. 2024 was $3.11. Hence, HilleVax's P/B Ratio of today is 0.61.


HilleVax Price-to-Tangible-Book Historical Data

The historical data trend for HilleVax's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Price-to-Tangible-Book Chart

HilleVax Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Tangible-Book
- - 2.36 2.88 0.67

HilleVax Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.88 3.41 3.48 0.47 0.67

Competitive Comparison of HilleVax's Price-to-Tangible-Book

For the Biotechnology subindustry, HilleVax's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HilleVax's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HilleVax's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where HilleVax's Price-to-Tangible-Book falls into.


;
;

HilleVax Price-to-Tangible-Book Calculation

HilleVax's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2024 )
=1.90/3.107
=0.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


HilleVax Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of HilleVax's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, Boston, MA, USA, 02118
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Executives
Robert Hershberg director, officer: President and CEO 3005 FIRST AVENUE, SEATTLE WA 98121
Shane Maltbie officer: Chief Financial Officer C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Aditya Kohli director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Astrid Borkowski officer: Chief Medical Officer C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Nanette Cocero director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100, BOSTON MA 02109
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Gary Dubin director C/O HILLEVAX, INC., 75 STATE STREET, SUITE 100 - #9995, BOSTON MA 02109
Jaime Sepulveda director C/O HILLEVAX INC., 75 STATE STREET 100 - #9995, BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET, CAMBRIDGE MA 02139
Shelley Chu director ONE WINTHROP SQUARE, SUITE 400, BOSTON MA 02110
Susan Michele Silbermann director C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, TWO UNION SQUARE, SEATTLE WA 98101
Julie L. Gerberding director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David A Socks officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130